COMMUNIQUÉS West-GlobeNewswire

Interpace Diagnostics Group Reports Third Quarter 2017 Financial Results, Business Progress and Recent Accomplishments
13/11/2017
Q3-2017 Net Revenues of Over $4 Million Growing 27% Over Prior Year Quarter Represents Fourth Straight Quarter of Sequential Revenue Growth Net Loss for the Quarter & Year to Date a 56% and 51% Improvement Over [...]
Novo Nordisk A/S - Share repurchase programme
13/11/2017
Bagsværd, Denmark, 13 November 2017 - On 1 November 2017, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No. 596/2014 of the European Parliament and Council of 16 April [...]
Reata Pharmaceuticals, Inc. Announces Third Quarter 2017 Financial and Operating Results
13/11/2017
IRVING, Texas, Nov. 13, 2017 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA ) (Reata or Company), a clinical-stage biopharmaceutical company, today announced financial results for the third quarter ended [...]
ProMIS Neurosciences Announces Third Quarter 2017 Results
13/11/2017
TORONTO, Ontario and CAMBRIDGE, Massachusetts, Nov. 13, 2017 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc., a company focused on the discovery and development of precision treatments for neurodegenerative diseases, [...]
Actinium Pharmaceuticals to Host Webcast to Introduce New Clinical Initiative in Collaboration with Leading Hematologist Dr. Gail Roboz
13/11/2017
- Dr. Gail Roboz, Director of the Leukemia Program and Professor of Medicine at Weill Cornell Medical College and NewYork-Presbyterian will introduce the planned clinical initiative on the webcast - Webcast to be held [...]
Clearside Biomedical’s Phase 1/2 Open Label Clinical Trial of CLS-TA With and Without Eylea in Diabetic Macular Edema Presented at the American Academy of Ophthalmology 2017 Annual Meeting
13/11/2017
ALPHARETTA, Ga., Nov. 13, 2017 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ: CLSD ), a late-stage clinical biopharmaceutical company developing first-in-class drug therapies to treat back-of-the-eye diseases, [...]
Neuralstem Reports Third Quarter 2017 Fiscal Results and Provides Clinical and Business Update
13/11/2017
GERMANTOWN, Md., Nov. 13, 2017 (GLOBE NEWSWIRE) -- Neuralstem, Inc. (NASDAQ: CUR ), a biopharmaceutical company focused on the development of nervous system therapies based on its neural stem cell technology, reported [...]
RedHill Biopharma Reports 2017 Third Quarter Financial Results
13/11/2017
RedHill maintains a debt-free balance sheet with $39.6 million in cash 1 at the end of the third quarter of 2017 In addition, an underwritten public offering of the Company’s American Depositary Shares (ADSs) is [...]
Society for Immunotherapy of Cancer (SITC) Recognizes Immunovaccine Researchers with Journal for ImmunoTherapy of Cancer (JITC) “Best Basic Science Paper Award”
13/11/2017
HALIFAX, Nova Scotia, Nov. 13, 2017 (GLOBE NEWSWIRE) -- Immunovaccine Inc. (TSX: IMV ) (OTCQX:IMMVF), a clinical stage immuno-oncology company, today announced that the Society for Immunotherapy of Cancer (SITC) has [...]
FDA Clears World’s First and Only Wire-Free Radar Breast Tumor Localization System for Long Term Implant Capabilities
13/11/2017
ALISO VIEJO, Calif., Nov. 13, 2017 (GLOBE NEWSWIRE) -- Cianna Medical, Inc. has received FDA clearance of the SAVI SCOUT® reflector for long term implant. The SAVI SCOUT reflector is an integral part of the SCOUT system [...]
Leap Therapeutics Reports Third Quarter 2017 Financial Results and Announces First Patient Dosed with DKN-01 and KEYTRUDA® (pembrolizumab) in Esophagogastric Cancer Trial
13/11/2017
CAMBRIDGE, Mass., Nov. 13, 2017 (GLOBE NEWSWIRE) -- Leap Therapeutics, Inc. (Nasdaq: LPTX ), a biotechnology company developing targeted and immuno-oncology therapeutics, today reported financial results for the third [...]
Melinta Therapeutics Reports First Patient Treated in Phase 2 Study of Topical Radezolid for Treatment of Acne
13/11/2017
NEW HAVEN, Conn., Nov. 13, 2017 (GLOBE NEWSWIRE) -- Melinta Therapeutics , Inc. (NASDAQ: MLNT ) a commercial-stage company developing and commercializing novel antibiotics to treat serious bacterial infections, [...]
ProQR Doses First LCA 10 Patient in Clinical Trial of QR-110, ProQR’s Lead Program for Genetic Blindness
13/11/2017
Key Updates The first patient has received the first dose of QR-110 in the Phase 1/2 safety & efficacy clinical trial (PQ-110-001: NCT03140969 ) in children and adults with Leber’s congenital amaurosis 10 (LCA 10). [...]
Spero Therapeutics Announces Underwriters’ Option Exercise
13/11/2017
CAMBRIDGE, Mass., Nov. 13, 2017 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO ), a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel [...]
Protalix BioTherapeutics Receives Positive Opinion for Orphan Designation for PRX-102 for the Treatment of Fabry Disease in the European Union
13/11/2017
CARMIEL, Israel, Nov. 13, 2017 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE: PLX ), a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic [...]
AC Immune SA Reports Third Quarter 2017 Financial Results and Corporate Update
13/11/2017
Expansion of pipeline with two new antibodies against proteins alpha-synuclein and TDP-43 Recruitment of first cohort completed for anti-beta vaccine targeting Alzheimer's symptoms in adults with Down syndrome Strong [...]
Jounce Therapeutics Reports Third Quarter 2017 Financial Results
13/11/2017
- Remain on track to announce preliminary efficacy data for the Phase 1/2 ICONIC study in 1H 2018 - - Strengthen leadership team and board with key new appointments - - Update full year financial guidance - - Company to [...]
Kamada Reports Financial Results for Third Quarter and First Nine Months of 2017
13/11/2017
Total Revenues for Third Quarter were $22.9 million, an 18% Increase Total revenues for first 9 months of 2017 were $67.1 million, a 26% Increase On Track to Achieve $100 Million in Total Revenues in 2017 Guiding to $ [...]
Real-World Data Analysis Shows That High Triglyceride Levels Are Associated With Increased Cardiovascular Events and Medical Costs
13/11/2017
Higher Rates of Myocardial Infarction (Heart Attack) and Revascularization Procedures in Patients with High Triglycerides Were Drivers of the Composite Outcome MACE Rate 35% Higher in Patients Who, Despite Statin [...]

Pages